MedTrace Logo

Buprenorphine in the Emergency Department

NCT03174067 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2017-06-02

No results posted yet for this study

Summary

This is a pilot randomized control trial randomizing patients presenting in opioid withdrawal to the emergency department to receive either one of clonidine (usual standard of care) or buprenorphine for their opioid withdrawal. Primary treatment outcome is attendance at a rapid access addiction medicine clinic within a few days of emergency room presentation. Secondary treatment outcome is treatment status with respect to opioid agonist treatment at one month post emergency room visit.

Conditions

  • Opioid Withdrawal
  • Opioid-use Disorder

Interventions

DRUG

Buprenorphine

The participant receives buprenorphine

DRUG

Clonidine

The participant receives clonidine

Sponsors & Collaborators

  • St. Joseph's Health Centre Toronto

    lead OTHER

Principal Investigators

  • Anita Srivastava, MD · University of Toronto

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2016-04-30
Completion
2016-11-30
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03174067 on ClinicalTrials.gov